APA (7th ed.) Citation

Wu, Z., Li, X., Huang, R., He, B., & Wang, C. (2025). Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis. Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, 43(1), 74-80. https://doi.org/10.1007/s10637-024-01499-z

Chicago Style (17th ed.) Citation

Wu, Zhaoquan, Xiting Li, Rui Huang, Binsheng He, and Chunjiang Wang. "Clinical Features, Treatment, and Prognosis of Pembrolizumab -induced Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies 43, no. 1 (2025): 74-80. https://doi.org/10.1007/s10637-024-01499-z.

MLA (9th ed.) Citation

Wu, Zhaoquan, et al. "Clinical Features, Treatment, and Prognosis of Pembrolizumab -induced Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, vol. 43, no. 1, 2025, pp. 74-80, https://doi.org/10.1007/s10637-024-01499-z.